Why Neogen (NEOG) is on investors’ radar today
Recent trading in Neogen (NEOG) has drawn attention after a stretch that includes a 2.0% move over the past day, modest gains over the past week, and a stronger showing over the past month.
See our latest analysis for Neogen.
At a share price of $9.54, Neogen’s recent 1 month share price return of 9.66% contrasts with a 3 month share price return decline of 4.70%, while the 1 year total shareholder return of 84.88% sits against a 5 year total shareholder return decline of 80.13%, indicating that momentum has been improving more recently even after a weak multi year stretch.
If this kind of rebound in sentiment has your attention, it could be a good moment to broaden your search and check out 33 healthcare AI stocks.
With the share price well below one estimate of value and a mixed record of long term returns, is Neogen still trading at a discount that could appeal to patient investors, or is the market already pricing in future growth?
Most Popular Narrative: 20.5% Undervalued
The most followed narrative puts Neogen’s fair value at $12.00, compared with the latest close of $9.54, and ties that gap to a detailed earnings and margin story.
Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.
Curious how a company with recent losses still earns an undervalued tag? This narrative leans heavily on margin repair, revenue reset, and a richer future earnings multiple.
Result: Fair Value of $12 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upside case still leans on smoother 3M Food Safety integration and a recovery in Animal Safety demand, both of which could disappoint and pressure margins.
Find out about the key risks to this Neogen narrative.
Next Steps
With sentiment clearly split between recent gains and a tougher long term record, it may be useful to review the complete picture for yourself, including the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If Neogen has you thinking about what else might be out there, now is a smart time to broaden your watchlist with a few focused stock ideas.
- Supercharge your hunt for mispriced quality by scanning 54 high quality undervalued stocks that combine solid fundamentals with appealing valuations.
- Prioritize staying power in tougher markets by checking out 74 resilient stocks with low risk scores built around resilient businesses and lower risk profiles.
- Get ahead of the crowd by reviewing a screener containing 25 high quality undiscovered gems before other investors start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com